The spring of 2026 is shaping up to be a pivotal period for U.S. tobacco giant Altria. As the company prepares for a significant change in its executive leadership, a recent regulatory development is forcing a strategic pivot within its portfolio of alternative products. The incoming management team is now poised to focus its efforts on nicotine pouches, moving away from vapor products, in a bid to counterbalance declining cigarette sales.
Salvatore Mancuso is set to take over the chief executive role from Billy Gifford on May 14, following Gifford’s more than three-decade tenure with the firm. Mancuso will inherit a company that remains on solid financial footing. Management recently reaffirmed its full-year earnings guidance, projecting adjusted earnings per share to land between $5.56 and $5.72. This consistency has provided support for the share price, which closed at 58.72 euros after advancing more than 20% since the start of the year.
Strategic Pivot Follows FDA Setback
A primary driver for this strategic realignment stems from a U.S. import and sales ban affecting NJOY ACE vaping devices. Altria does not anticipate returning the product to the market in 2026. This regulatory hurdle compels the corporation to channel its investments in the smoke-free segment toward its “on! PLUS” nicotine pouch brand.
Having received FDA authorization last December, the company is currently gearing up for a nationwide rollout of these pouches in the first half of the year. The market opportunity appears substantial, with the number of users of oral tobacco products in the U.S. tripling over the past three years to reach 3.5 million.
Should investors sell immediately? Or is it worth buying Altria?
Dividend Reliability Anchored by Pricing Power
Funding for this strategic shift continues to be generated by Altria’s core cigarette operations. While industry-wide sales volumes in the United States are in a persistent state of decline, the company effectively offsets this through disciplined price increases. The operating margin for this segment recently expanded by 1.8 percentage points to reach 63.4%.
This robust profitability enables Altria to reliably return capital to shareholders, in addition to an existing share repurchase program exceeding $1 billion. Investors should note the following key dates for the upcoming quarterly distribution:
- Ex-Dividend Date: March 25, 2026
- Record Date: March 25, 2026
- Quarterly Dividend: $1.06 per share
- Payment Date: April 30, 2026
When Sal Mancuso assumes the CEO position in May, his operational priorities will be clearly defined. The enduring pricing power of the traditional cigarette business will afford him the necessary financial flexibility to aggressively pursue the national expansion of “on! PLUS” pouches and manage the absence of the NJOY products from the market.
Ad
Altria Stock: Buy or Sell?! New Altria Analysis from March 17 delivers the answer:
The latest Altria figures speak for themselves: Urgent action needed for Altria investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 17.
Altria: Buy or sell? Read more here...









